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Diagnosing Alzheimer’s disease (AD) early
is itself a controversial topic—not to be
addressed here—, as many believe that
adequate therapeutics are not available
for modifying the course of the disease.
Although this may be the case today, it
is perhaps due to the fact that existing
therapies do not have positive results as
the disease process is too far advanced.
Distinguishing the cases who will progress
to AD among individuals with mild cog-
nitive impairment (MCI), would allow
early administration of these currently and
future available treatments. Together, this
can prolong a meaningful life and also
reduce the burden on caregivers as well
as the cost of care, now that both the
prevalence and cost of AD are rising at a
rapid rate.
However, diagnosing AD at its early
stage still remains a challenge, even in
specialized AD centers. Numerous studies
suggest that CSF biomarkers have a high
potential as diagnostic tools: the measure-
ment of the 2 key AD proteins, Amyloid-
beta and Tau, is very helpful for detecting
neuropathologic changes related to AD
early. CSF levels of Amyloid-beta, but not
of Tau, are fully changed already 5–10 years
before the onset of clinical AD (Buchhave
et al., 2012). CSF TAU changes some time
later, when the brain atrophy starts, being
a good marker of injury. Thus, in subjects
with MCI and evidence of amyloid pathol-
ogy, CSF Tau can predict further cognitive
decline (van Rossum et al., 2012).
According to sensitivity, specificity, and
predictive values of CSF biomarkers, one
may think neurologists should be sharp-
ening their lumbar puncture needles in
order to improve their diagnostic accu-
racy in cases of MCI. Nevertheless, there
is a wide range of attitudes and beliefs
about the convenience and feasibility of
lumbar punctures (LP; commonly referred
to as spinal taps), and its practical value
in the management of patients today. LP
may be regarded as invasive or compli-
cated and time consuming. In addition
patients may have fear to undergo LP.
One of the most controversial issues when
discussing CSF biomarkers for early AD
diagnosis has to do with the collection pro-
cedure itself. A debate exists on whether
or not this technique can and should be
used regularly, or if it is still too risky
for routine practice. Clinically, LP are per-
formed routinely in clinics for various
laboratory analyses to diagnose diseases
such as meningitis, encephalitis or inflam-
matory diseases like Multiple Sclerosis as
well as to inject spinal anaesthetics or
chemotherapy drugs. However, many still
feel that the benefits of its use for test-
ing AD biomarkers do not outweigh the
risks.
As a result, the use of LP for test-
ing CSF biomarkers in the diagnosis
of AD is surprisingly culturally depen-
dent and subject to changes in fash-
ion today. From clinicians who support
its use in daily clinical practice (Ariza-
Zafra and Torrente-Orihuela, 2005; Lanari
and Parnetti, 2009; Galluzzi et al., 2013)
and countries where lumbar punture is
almost a routine (Scandinavian coun-
tries, The Netherlands.) to other territo-
ries (Northamerica) where it is regarded
as a very serious issue and used for
research purposes under strict protocols
only (Wilner, 2010; Cummings, 2011).
Some studies have already assessed the
risks of LP; and the procedure seems to
be both “safe and acceptable” to do. In a
multi-site US study, 342 people underwent
428 LP. Side effects such as pain, anxiety
and the well-known post-lumbar punc-
ture headaches (PLPHAS) were quantified
and compared to controls. Overall, pain
and anxiety levels were low as rated on
a visual analog scale but generally were
rated higher in the younger normal sub-
jects as compared to the older participants.
This theme remains true amongst studies
looking at PLPHA frequency and sever-
ity, where those who are younger are at
higher risk, especially females (Evans et al.,
2000). In terms of PLPHAs, they were
unrelated to factors such as the position
during the procedure (seated vs. lying) and
the frequency of these headaches was low-
est in the MCI/AD (over age 60) group
than any other subject group. This is a
promising conclusion as far as AD is con-
cerned, as all of the participants are older
and many have MCI or AD. Other study
designed to assess LP procedures specif-
ically in patients with AD also demon-
strated that LP performed with a 24 g
Sprotte atraumatic needle (blunt, “bul-
let” tip) is a well-tolerated procedure, with
good acceptability (Peskind et al., 2009).
As many other medical techniques, the
more often a procedure is done, the safer it
becomes. In order to obtain more in depth
knowledge on the factors affecting the
complications of LP for testing biomark-
ers in patients with cognitive impairment,
the Alzheimer’s Association is supporting
a multi-center feasibility study. This study
will allow to establish the incidence of
post-LP headache and other complications
in cases with cognitive disturbances and
to know the factors related to the occur-
rence of post-LP headache, including type
of center/experience of physician, patient
characteristics (e.g., diagnosis, cognitive
function), patient attitude/knowledge on
LP and the LP procedure itself.
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Once it seems that complications
related to LP for testing biomarkers in
patients with cognitive decline are limited
and controllable, next step should be to
achieve consensus in order to state which
patients should be offered a CSF analy-
sis and how to interprect results in terms
of clinical management. There is also a
need to homogenize the different analy-
sis techniques, protocols, and establishing
universal cut-off levels for the biomarkers.
Fortunately several international projects
are ongoing in these regards. Hopefully
we are envisioning the possibility of using
LP for an earlier diagnosis in most AD
patients.
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